Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | PDE4A | P27815 | 2/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 4/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14507751 | 0.90 | PDE4A (0.61) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL14507749 | 0.89 | PDE4A (0.60) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL14507748 | 0.87 | PDE4A (0.58) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL7459613 | 0.85 | PDE4A (0.54) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL27483420 | 0.85 | PDE4A (0.53) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL14507747 | 0.85 | ADORA2A (0.64) | LMNACYP1A2NFKB1ACHEPDE4A | |
| Ammonia Solution, Strong SCHEMBL8658618 | 0.84 | PDE4A (0.52) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL10346509 | 0.83 | PDE4A (0.76) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL7456005 | 0.83 | ADORA2B (0.55) | LMNACYP1A2NFKB1ACHEPDE4A | |
| SCHEMBL7455411 | 0.83 | PDE4A (0.51) | LMNACYP1A2NFKB1ACHEPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105878-A1 | Purine formulations and methods for managing disorders | REAUME ANDREW | 2007-05-10 | — | — | US | disclosed |
| US-20070105878-A1 | Purine formulations and methods for managing disorders | REAUME ANDREW | 2007-05-10 | — | — | US | disclosed |
| WO-2007041506-A1 | PURINE FORMULATIONS AND METHODS FOR MANAGING DISORDERS | MELIOR DISCOVERY, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105878-A1 | Purine formulations and methods for managing disorders | TPMT, UMPS, SLC10A2 | LMNA 2994/4885CYP1A2 2776/4885NFKB1 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.